We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions regarding GSK (GlaxoSmithKline Plc) reflect a cautious yet hopeful sentiment as they consider potential shifts in market dynamics for the upcoming year. Participants highlighted a pivotal change in focus towards broader markets, particularly in light of the FTSE 100 reaching record highs, which may benefit "buy and hold" dividend companies such as GSK. Despite historical challenges, one investor expressed optimism that "it is time they had their day in the sun," indicating a belief in the company's latent potential.
Financially, GSK was noted for its attractive valuation metrics, with a trailing P/E ratio of 8.71 and a forecasted ratio of 8.4, positioning it at the lower end of its peer group—averaging 29.1 among similar firms. This has led some investors to assert that GSK appears "very undervalued," which could present an opportunity for future gains. Additionally, recent developments regarding the European Commission's expansion of the approval for GSK's Jemperli treatment were highlighted as a significant positive, potentially signaling advancement in their product pipeline. Investor sentiment remains mixed, with some expressing frustration over external analysts' target price adjustments, juxtaposed with optimism about the company's underlying growth prospects.
Show more
GSK plc has achieved a significant milestone with the recent European Commission approval of its drug Jemperli (dostarlimab) for an expanded use in treating adult patients with primary advanced or recurrent endometrial cancer. This expansion allows the drug to be used in combination with chemotherapy, represented by carboplatin and paclitaxel, targeting all adult patients who are candidates for systemic therapy. This approval is particularly notable as it includes patients with MMRp/MSS tumors, which account for approximately 75% of endometrial cancer cases. The decision is based on the promising results from the RUBY Part 1 clinical trial, which demonstrated a median overall survival of 44.6 months for Jemperli in combination with chemotherapy, compared to only 28.2 months for chemotherapy alone.
The enhanced approval of Jemperli underscores GSK's commitment to advancing cancer treatment options and represents a pivotal growth opportunity within its oncology portfolio. This strategic development is expected to strengthen GSK’s position in the market and enhance its revenue potential from the oncology segment, particularly as the only immuno-oncology treatment to significantly improve overall survival in this patient population. As GSK continues to explore further applications of its therapies, these developments may also bode well for future financial performance.
Show more
I bought a few more a few hours ago at 12.98.Major support here Let's see how this rolls. |
Good news today re. successful Phase lll Linerixibat results. |
Gecko |
Are you trying to initiate a war here Gecko ?? |
Yawn, your TDS is boring Jubber. |
The general market has got a new strain of Trump/Kennedy induced diarrhoea |
Yes good news followed by bad news, daily. |
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) |
I'll add my two pennyworth |
Interesting points made here. I'm assuming by individuals who hold significant amounts.?..the fact it has become more noteably political is intriguing. |
#743. What has that post got to do with GSK? |
Dr Biotech |
That's ok - they'll raise it again after the shareprice reaches 1500p, 1700p etc. |
Wow, I know analysts are useless but that's a big cut. |
These brokers are good for nothing at all. |
These brokers are so clever cutting price targets after the event...10yrs old could that... |
Deutsche Bank cuts target price to 1350p from 1700p |
Further falls as Tariffs hit. |
is RFK jnr's appointment likely to be acceptable to and confirmed by congress? It seems even some Republican members are extremely sceptical of the anti-vax and FDA rhetoric, believing that vaccination is probably the biggest medical advance of all time after clean drinking water. |
I had this sell off attributed to the legal difficulties currently being experienced by AZN big wigs in China,this was then followed by the appointment of a Health Secretly in the USA who is as deluded as trump. |
First UK case was jan 2020. Part of the problem with Covid whilst obviously a serious virus, was the misinformation given by the likes of Zero Hedge and reposted by useful idiots on other forums. Doing Russia's bidding, but too thick to realise. Would have helped of course if the Chinese had been more honest and open. |
Washingmachine 16 Nov '24 - 07:08 - 33722 |
And he’s still had a far better life than 99 percent .. |
Type | Ordinary Share |
Share ISIN | GB00BN7SWP63 |
Sector | Pharmaceutical Preparations |
Bid Price | 1,356.00 |
Offer Price | 1,356.50 |
Open | 1,365.00 |
Shares Traded | 5,013,886 |
Last Trade | 16:29:58 |
Low - High | 1,353.00 - 1,370.00 |
Turnover | 30.33B |
Profit | 4.93B |
EPS - Basic | 1.1889 |
PE Ratio | 11.41 |
Market Cap | 56.52B |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads